News

NEW BREAKTHROUGH TEST DETECTS AND PREDICTS SEVERITY OF COVID-19

CHARLOTTESVILLE, Va., /PRNewswire/ — AMPEL BioSolutions today announced a breakthrough in precision and personalized medicine that can detect and predict the severity of COVID-19 in patients while also determining the best treatment options for each specific case. The company’s new approach, through a simple blood test, will ultimately accelerate the means of providing effective treatments to the right people at the right time and potentially stem the serious illness caused by SARS-CoV-2 infection that can lead to lung damage or death.

AMPEL’s new genomic test, known as CovGENE®, has been validated by a longitudinal study in partnership with physicians in the Division of Pulmonary and Critical Care Medicine of the University of Virginia Medical Center. With careful analysis of patients admitted to the UVA Intensive Care Unit, CovGENE® demonstrated remarkable precision with a greater than 90-percent rate of accuracy. CovGENE®, can be administered by drawing a patient’s blood to quickly ascertain whether a Covid-19 patient will have a mild, moderate, or severe outcome. The findings are detailed in a paper published today by Frontiers in Immunology.

“This unique collaboration with our colleagues from the University of Virginia has provided an easy and novel means to assess an individual patient’s response to the SARS-CoV-2 virus and predict the clinical outcome,” said Dr. Peter Lipsky, AMPEL Chief Medical Officer, CEO and co-founder. “Now that this unique approach has been validated, we look forward to its rapid development as a precision medicine tool that can improve the outcome of patients with Covid-19 and reduce the number of hospitalizations, especially the most vulnerable.”

AMPEL is currently working to secure a partnership with a diagnostic testing company to make CovGENE® available to the general public at a crucial time as different variants continue to emerge across the globe and with winter around the corner, when major spikes can occur. CovGENE® also holds promise in predicting long COVID, an elusive diagnosis the medical community is still trying to fully understand.

“We have come far in the prevention and treatment of COVID-19 in the past 2 years. Regardless, we still struggle to identify patients at highest risk for severe disease. Our study uses a gene analysis approach to identify an immune cell signature, distinct from other respiratory illnesses that correlates with worse outcome,” said Dr. Alexandra Kadl, lead author from the University of Virginia Division of Pulmonary and Critical Care Medicine. “This knowledge will help evaluate patients’ immune profile with commonly, readily available assays to identify patients at risk for bad outcome that would benefit from closer monitoring and advanced therapies to aid their recovery.”

AMPEL has become a bio-industry leader in precision medicine by utilizing a data driven and machine learning approach to positively impact health care by allowing physicians to identify the cause of patient disease symptoms and select appropriate treatments more precisely.  AMPEL’s co-founders Dr. Amrie Grammer and Dr. Peter Lipsky, are internationally known for their work in genomics, and were also recent panelists at the Precision Medicine World Conference.

Read more here.

Recent News

02/01/2023

Engineered BioPharmaceuticals to Expand in Virginia

Governor Glenn Youngkin announced that Engineered BioPharmaceuticals, Inc., a pharmaceutical engineering and manufacturing company dedicated to advancing cost effective, state-of-the-art medicine, will invest $6.1 million to expand in the City of Danville. The company will expand from its current lab space in the Dan River Business Development Center into its first standalone manufacturing facility at

02/01/2023

Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced it has entered into an option agreement for the sale of the assets of Purnovate, Inc. (“Purnovate”), a wholly owned subsidiary of Adial, to Adenomed, LLC (“Adenomed”), a new company formed by Purnovate

01/31/2023

AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia

AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic pain syndromes, such as fibromyalgia. Revealed in the peer-reviewed journal Lupus Science and Medicine, the paper details AMPEL’s breakthrough approach to characterize the underlying disease activity from gene expression data obtained from patient blood samples. The FibroGENE® lab